Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ford Motor Company (F) vs Neurocrine Biosciences Inc (NBIX) Price & Performance

Ford Motor CompanyTrade
Neurocrine Biosciences IncTrade

Price performance (Past 24H)

Key statistics

Ford Motor Company vs Neurocrine Biosciences Inc — how do they compare? Ford Motor Company trades at $13.98 (market cap $55.83B), while Neurocrine Biosciences Inc trades at $161.94 (market cap $16.76B). The key difference: Ford Motor Company is far larger — about 3.3× Neurocrine Biosciences Inc's market cap, and Ford Motor Company pays a 4.29% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.

FNBIX
Market Cap
$55.83B$16.76B
Sector
Consumer CyclicalHealth
52-Week High
$17.44$185.50
52-Week Low
$11.21$123.10
Enterprise Value
$187.79B$16.78B
Dividend Yield
4.29%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ford Motor Company

Ford (F) trades at $13.98, up 1.38% with a bullish technical signal despite mixed fundamentals. The company reported negative net income of -$8.18B in 2025 but maintains strong operating cash flow of $21.28B. Recent news highlights Ford's new $28,350 Fathom EV truck launch for 2027, targeting affordable electric vehicles while managing EV transition costs through its profitable commercial Pro segment.

Outlook remains cautious with analyst consensus at $16.00 (43% buy ratings). Key opportunities include EV expansion and dividend stability ($0.15 quarterly), while risks involve persistent net losses, high debt levels (56.49% debt-to-asset), and competitive EV market pressures. The stock offers value with low P/E (11.84) but requires monitoring of profitability turnaround.

Neurocrine Biosciences Inc

Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.

The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Ford Motor Company

Ford Motor Company designs, manufactures, and services cars and trucks. The Company also provides vehicle-related financing, leasing, and insurance through its subsidiary.

Read more on F

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.

Read more on NBIX